Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Crism TherapeuticsSTU:A7L 37 PEG Ratio is 0.00 as of Jul. 21, 2026. GuruFocus rates STU:A7L with a GF Score™ of 37/100. The stock has 3 warning signs investors should review. Among 93 Biotechnology companies, Crism Therapeutics ranks worse than 1075267.74% on this metric.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Crism Therapeutics's PEG Ratio or its related term are showing as below:
STU:A7L's PEG Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 1.97 * Ranked among companies with meaningful PEG Ratio only.
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Crism Therapeutics (STU:A7L) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Crism Therapeutics PEG Ratio Related Terms
Crism Therapeutics PEG Ratio Historical Data
* Premium members only.
The historical data trend for Crism Therapeutics's PEG Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Crism Therapeutics's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Crism Therapeutics PEG Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Crism Therapeutics's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Crism Therapeutics's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Crism Therapeutics (STU:A7L) has a PEG Ratio of 0.00 as of Jul. 21, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Crism Therapeutics and its competitors. According to the industry distribution chart, Crism Therapeutics ranks #999999 out of 93 companies in the Biotechnology industry.
Is Crism Therapeutics' PEG Ratio too high?
Crism Therapeutics' current PEG Ratio is 0.00. Based on the distribution chart, Crism Therapeutics ranks #999999 out of 93 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Crism Therapeutics has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Crism Therapeutics' PEG Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Crism Therapeutics ranks #999999 out of 93 companies for PEG Ratio. This places Crism Therapeutics in the lower half of its industry. The industry median PEG Ratio is 1.97. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Biotechnology company?
The median PEG Ratio among Biotechnology companies is 1.97, based on 93 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Crism Therapeutics and its competitors. For the Biotechnology industry, the median PEG Ratio is 1.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Crism Therapeutics's current PEG Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Crism Therapeutics stock overvalued right now?
Crism Therapeutics (STU:A7L) has a current PEG Ratio of 0.00. The current PEG Ratio is 0.00. Crism Therapeutics' overall GF Score™ is 37/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Crism Therapeutics (STU:A7L), the current PEG Ratio is 0.00 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Crism Therapeutics Corp has developed a drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs. Its product ChemoSeed which is in its clinical trial phase, can be implanted directly into the tumour or the resection margin following the removal of a tumour. The company also provides consultancy and formulation services to its clients assisting them with pharmaceutical formulation and development.
37GF Score
Get the complete analysis for STU:A7L
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:A7L has been successfully added to your 
